Synopsis
Protein turnover is crucial in maintaining cellular homeostasis and this process is largely controlled by the Ubiquitin Proteasome Pathway (UPP). The pathway consists of an enzymatic cascade that links the polypeptide cofactor Ubiquitin to specific protein targets, which mark them for degradation by the proteasome. This cascade is highly regulated and impacts virtually all cellular processes including cell cycle progression, cell proliferation, cell differentiation and apoptosis. Malfunction of the UPP has been implicated in the development of diseases such as cancer, immune disorders and neurodegeneration.The ability to understand and manipulate the UPP is a major objective in being able to manage disease biology. While the validity of this approach was first exemplified by the proteasome inhibitor bortezomib, approved by the FDA in 2003 and used in the treatment of multiple myeloma and mantle cell lymphoma, subsequent advances in understanding the role of different components in the UPP have allowed the development of other high quality chemical probes and inhibitors.
This meeting aims to showcase recent innovations by scientists working in both academia and industry in this exciting and rapidly expanding field.
Attendees
SCI Members attending this meeting are able to claim CPD pointsProgramme
10.00 Registration and refreshments10.25 Opening remarks
10.30 PROTACs: Induced Protein Degradation as a Therapeutic Strategy
Craig Crews, Yale Center for Molecular Discovery
11.30 Ubiquitin system modulation: strategies and technologies
Satpal Virdee, University of Dundee
12.00 Chemical Ubiquitination
Huib Ovaa, Leiden University Medical Centre
12.30 Lunch and exhibition
14.00 From Pan-Kinase Promiscuity to Selective Degradation using PROTACs
Christopher Tinworth, GlaxoSmithKline
14.30 Inhibitors of the E2 ubiquitin conjugating enzyme Rad6: discovery and anticancer properties
Andrew Westwell, Cardiff University
15.00 Refreshments and exhibition
15.30 Enabling and supporting ubiquitin system targeted drug discovery
Jason Brown, Ubiquigent
16.00 Ubiquitin -Omics for Target Discovery in Human Disease
Benedikt Kessler, Nuffield Department of Medicine
16.30 Protein Degradation by In-鈥婥ell Self-鈥婣ssembly of Proteolysis Targeting Chimeras
Tom Heightman, Astex Pharmaceuticals
17.00 Closing remarks and conference close
Keynote speaker
Craig Crews, Yale Center for Molecular DiscoveryPROTACs: Induced Protein Degradation as a Therapeutic Strategy
Organising Committee
Nicola Chessum, The Institute of Cancer ResearchDavid Leese, Concept Life Sciences
Jayshree Mistry
Manisha Naik, Lilly
Delegate Fees
Standard fees after Tuesday 18 April 2017GB拢130 . . . . . . . . . . . . . . . . SCI Member
GB拢50 . . . . . . . . . . . . . . . . . SCI Student Member
GB拢70 . . . . . . . . . . . . . . . . . SCI Subsidised Member
GB拢170 . . . . . . . . . . . . . . . . Non-Member
SCI Platinum Corporate Members receive 25% off the above rates
Exhibitors
UbiquigentSponsors
Evotec Ltd
GSK
